Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 460

1.

Cognitive and brain structural changes in long-term oligodendroglial tumor survivors.

Cayuela N, Jaramillo-Jiménez E, Càmara E, Majós C, Vidal N, Lucas A, Gil-Gil M, Graus F, Bruna J, Simó M.

Neuro Oncol. 2019 Aug 9. pii: noz130. doi: 10.1093/neuonc/noz130. [Epub ahead of print]

PMID:
31549152
2.

Late-onset neuromyelitis optica spectrum disorder: The importance of autoantibody serostatus.

Sepulveda M, Delgado-García G, Blanco Y, Sola-Valls N, Martinez-Lapiscina EH, Armangué T, Montejo C, Pulido-Valdeolivas I, Martinez-Hernandez E, Ariño H, Escudero D, Ruiz-García R, Llufriu S, Dalmau J, Graus F, Saiz A.

Neurol Neuroimmunol Neuroinflamm. 2019 Aug 30;6(6). pii: e607. doi: 10.1212/NXI.0000000000000607. Print 2019 Nov.

3.

HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease.

Gaig C, Ercilla G, Daura X, Ezquerra M, Fernández-Santiago R, Palou E, Sabater L, Höftberger R, Heidbreder A, Högl B, Iranzo A, Santamaria J, Dalmau J, Graus F.

Neurol Neuroimmunol Neuroinflamm. 2019 Aug 12;6(6). pii: e605. doi: 10.1212/NXI.0000000000000605. Print 2019 Nov.

4.

Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program.

Janin M, Ortiz-Barahona V, de Moura MC, Martínez-Cardús A, Llinàs-Arias P, Soler M, Nachmani D, Pelletier J, Schumann U, Calleja-Cervantes ME, Moran S, Guil S, Bueno-Costa A, Piñeyro D, Perez-Salvia M, Rosselló-Tortella M, Piqué L, Bech-Serra JJ, De La Torre C, Vidal A, Martínez-Iniesta M, Martín-Tejera JF, Villanueva A, Arias A, Cuartas I, Aransay AM, La Madrid AM, Carcaboso AM, Santa-Maria V, Mora J, Fernandez AF, Fraga MF, Aldecoa I, Pedrosa L, Graus F, Vidal N, Martínez-Soler F, Tortosa A, Carrato C, Balañá C, Boudreau MW, Hergenrother PJ, Kötter P, Entian KD, Hench J, Frank S, Mansouri S, Zadeh G, Dans PD, Orozco M, Thomas G, Blanco S, Seoane J, Preiss T, Pandolfi PP, Esteller M.

Acta Neuropathol. 2019 Aug 19. doi: 10.1007/s00401-019-02062-4. [Epub ahead of print]

PMID:
31428936
5.

An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models.

Dalmau J, Armangué T, Planagumà J, Radosevic M, Mannara F, Leypoldt F, Geis C, Lancaster E, Titulaer MJ, Rosenfeld MR, Graus F.

Lancet Neurol. 2019 Nov;18(11):1045-1057. doi: 10.1016/S1474-4422(19)30244-3. Epub 2019 Jul 17. Review.

PMID:
31326280
6.

Characterization of the sleep disorder of anti-IgLON5 disease.

Gaig C, Iranzo A, Cajochen C, Vilaseca I, Embid C, Dalmau J, Graus F, Santamaria J.

Sleep. 2019 Jun 14. pii: zsz133. doi: 10.1093/sleep/zsz133. [Epub ahead of print]

PMID:
31198936
7.

LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy.

Pascual-García M, Bonfill-Teixidor E, Planas-Rigol E, Rubio-Perez C, Iurlaro R, Arias A, Cuartas I, Sala-Hojman A, Escudero L, Martínez-Ricarte F, Huber-Ruano I, Nuciforo P, Pedrosa L, Marques C, Braña I, Garralda E, Vieito M, Squatrito M, Pineda E, Graus F, Espejo C, Sahuquillo J, Tabernero J, Seoane J.

Nat Commun. 2019 Jun 11;10(1):2416. doi: 10.1038/s41467-019-10369-9.

8.

Caveats and Pitfalls of SOX1 Autoantibody Testing With a Commercial Line Blot Assay in Paraneoplastic Neurological Investigations.

Ruiz-García R, Martínez-Hernández E, García-Ormaechea M, Español-Rego M, Sabater L, Querol L, Illa I, Dalmau J, Graus F.

Front Immunol. 2019 Apr 12;10:769. doi: 10.3389/fimmu.2019.00769. eCollection 2019.

9.

Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors.

Graus F, Dalmau J.

Nat Rev Clin Oncol. 2019 Sep;16(9):535-548. doi: 10.1038/s41571-019-0194-4. Review.

PMID:
30867573
10.

Editorial: Widening the spectrum of inflammatory disorders of the central nervous system: an update on autoimmune neurology.

Graus F.

Curr Opin Neurol. 2019 Jun;32(3):449-451. doi: 10.1097/WCO.0000000000000682. No abstract available.

PMID:
30844862
11.

Autoimmune seizures and epilepsy.

Geis C, Planagumà J, Carreño M, Graus F, Dalmau J.

J Clin Invest. 2019 Mar 1;129(3):926-940. doi: 10.1172/JCI125178. Epub 2019 Feb 4. Review.

12.

Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease.

Pedreño M, Sepúlveda M, Armangué T, Sabater L, Martínez-Hernandez E, Arrambide G, Blanco Y, Llufriu S, Martínez-Lapiscina EH, Mulero P, Sola-Valls N, Ruiz-García R, Tintoré M, Dalmau J, Graus F, Saiz A.

Mult Scler Relat Disord. 2019 Feb;28:230-234. doi: 10.1016/j.msard.2019.01.007. Epub 2019 Jan 3.

PMID:
30623863
13.

A case of recurrent MOG antibody positive bilateral optic neuritis and anti-NMDAR encephalitis: Different biological evolution of the two associated antibodies.

Rojc B, Podnar B, Graus F.

J Neuroimmunol. 2019 Mar 15;328:86-88. doi: 10.1016/j.jneuroim.2018.12.003. Epub 2018 Dec 14.

PMID:
30599296
14.

A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis.

Balu R, McCracken L, Lancaster E, Graus F, Dalmau J, Titulaer MJ.

Neurology. 2019 Jan 15;92(3):e244-e252. doi: 10.1212/WNL.0000000000006783. Epub 2018 Dec 21.

15.

Corrigendum.

Cayuela N, Jaramillo-Jiménez E, Majós C, Velasco R, Boget T, Graus F, Bruna J, Simó M.

Neuro Oncol. 2018 Nov 20. doi: 10.1093/neuonc/noy179. [Epub ahead of print] No abstract available.

PMID:
30462315
16.

The utility of anti-SOX2 antibodies for cancer prediction in patients with paraneoplastic neurological disorders.

Maddison P, Titulaer MJ, Verschuuren JJ, Gozzard P, Lang B, Irani SR, Sabater L, Graus F, Murray A, Chapman CJ.

J Neuroimmunol. 2019 Jan 15;326:14-18. doi: 10.1016/j.jneuroim.2018.11.003. Epub 2018 Nov 8.

17.

Paraneoplastic stiff person syndrome with small cell carcinoma of the bladder and anti-Ri antibodies.

de Albóniga-Chindurza A, Riva E, Jiménez-Huete A, Graus F, Franch O.

Clin Neurol Neurosurg. 2018 Oct;173:194-195. doi: 10.1016/j.clineuro.2018.08.020. Epub 2018 Aug 16.

PMID:
30165320
18.

Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis.

Armangue T, Spatola M, Vlagea A, Mattozzi S, Cárceles-Cordon M, Martinez-Heras E, Llufriu S, Muchart J, Erro ME, Abraira L, Moris G, Monros-Giménez L, Corral-Corral Í, Montejo C, Toledo M, Bataller L, Secondi G, Ariño H, Martínez-Hernández E, Juan M, Marcos MA, Alsina L, Saiz A, Rosenfeld MR, Graus F, Dalmau J; Spanish Herpes Simplex Encephalitis Study Group.

Lancet Neurol. 2018 Sep;17(9):760-772. doi: 10.1016/S1474-4422(18)30244-8. Epub 2018 Jul 23.

19.

The Sleep Disorder in Anti-lgLON5 Disease.

Gaig C, Iranzo A, Santamaria J, Graus F.

Curr Neurol Neurosci Rep. 2018 May 23;18(7):41. doi: 10.1007/s11910-018-0848-0. Review.

PMID:
29796717
20.

Antibodies against cell adhesion molecules and neural structures in paraneoplastic neuropathies.

Siles AM, Martínez-Hernández E, Araque J, Diaz-Manera J, Rojas-Garcia R, Gallardo E, Illa I, Graus F, Querol L.

Ann Clin Transl Neurol. 2018 Mar 26;5(5):559-569. doi: 10.1002/acn3.554. eCollection 2018 May.

21.

Encephalitis with mGluR5 antibodies: Symptoms and antibody effects.

Spatola M, Sabater L, Planagumà J, Martínez-Hernandez E, Armangué T, Prüss H, Iizuka T, Caparó Oblitas RL, Antoine JC, Li R, Heaney N, Tubridy N, Munteis Olivas E, Rosenfeld MR, Graus F, Dalmau J.

Neurology. 2018 May 29;90(22):e1964-e1972. doi: 10.1212/WNL.0000000000005614. Epub 2018 Apr 27.

22.

Seronegative and seropositive autoimmune autonomic ganglionopathy (AAG): Same clinical picture, same response to immunotherapy.

Tijero B, Del Pino R, Pérez-Concha T, Acera MA, Gabilondo I, Berganzo K, Graus F, Martinez-Alday JD, Barcena J, Gómez-Esteban JC.

J Neuroimmunol. 2018 Jun 15;319:68-70. doi: 10.1016/j.jneuroim.2018.03.018. Epub 2018 Apr 4.

PMID:
29685292
23.

Syndrome and outcome of antibody-negative limbic encephalitis.

Graus F, Escudero D, Oleaga L, Bruna J, Villarejo-Galende A, Ballabriga J, Barceló MI, Gilo F, Popkirov S, Stourac P, Dalmau J.

Eur J Neurol. 2018 Aug;25(8):1011-1016. doi: 10.1111/ene.13661. Epub 2018 May 21. Erratum in: Eur J Neurol. 2018 Oct;25(10):1303.

24.

Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid.

Martínez-Ricarte F, Mayor R, Martínez-Sáez E, Rubio-Pérez C, Pineda E, Cordero E, Cicuéndez M, Poca MA, López-Bigas N, Ramon Y Cajal S, Vieito M, Carles J, Tabernero J, Vivancos A, Gallego S, Graus F, Sahuquillo J, Seoane J.

Clin Cancer Res. 2018 Jun 15;24(12):2812-2819. doi: 10.1158/1078-0432.CCR-17-3800. Epub 2018 Apr 3.

25.

Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor.

Hara M, Martinez-Hernandez E, Ariño H, Armangué T, Spatola M, Petit-Pedrol M, Saiz A, Rosenfeld MR, Graus F, Dalmau J.

Neurology. 2018 Apr 17;90(16):e1386-e1394. doi: 10.1212/WNL.0000000000005329. Epub 2018 Mar 16.

26.

Antibody-Mediated Encephalitis.

Dalmau J, Graus F.

N Engl J Med. 2018 Mar 1;378(9):840-851. doi: 10.1056/NEJMra1708712. Review. No abstract available.

PMID:
29490181
27.

Autoimmune encephalitis with GABAA receptor antibodies in a 10-year-old girl.

Figlerowicz M, Kemnitz P, Mania A, Mazur-Melewska K, Tomczak E, Kuls K, Jończyk-Potoczna K, Graus F, Służewski W.

Clin Neurol Neurosurg. 2018 Jan;164:160-163. doi: 10.1016/j.clineuro.2017.12.012. Epub 2017 Dec 12.

PMID:
29245105
28.

GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma.

Moreno M, Pedrosa L, Paré L, Pineda E, Bejarano L, Martínez J, Balasubramaniyan V, Ezhilarasan R, Kallarackal N, Kim SH, Wang J, Audia A, Conroy S, Marin M, Ribalta T, Pujol T, Herreros A, Tortosa A, Mira H, Alonso MM, Gómez-Manzano C, Graus F, Sulman EP, Piao X, Nakano I, Prat A, Bhat KP, de la Iglesia N.

Cell Rep. 2017 Nov 21;21(8):2183-2197. doi: 10.1016/j.celrep.2017.10.083.

29.

Seizure-susceptible brain regions in glioblastoma: identification of patients at risk.

Cayuela N, Simó M, Majós C, Rifà-Ros X, Gállego Pérez-Larraya J, Ripollés P, Vidal N, Miró J, Gil F, Gil-Gil M, Plans G, Graus F, Bruna J.

Eur J Neurol. 2018 Feb;25(2):387-394. doi: 10.1111/ene.13518. Epub 2017 Dec 11.

PMID:
29115706
30.

Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates.

Sepúlveda M, Aldea M, Escudero D, Llufriu S, Arrambide G, Otero-Romero S, Sastre-Garriga J, Romero-Pinel L, Martínez-Yélamos S, Sola-Valls N, Armangué T, Sotoca J, Escartín A, Robles-Cedeño R, Ramió-Torrentà L, Presas-Rodríguez S, Ramo-Tello C, Munteis E, Pelayo R, Gubieras L, Brieva L, Ortiz N, Hervás M, Mañé-Martínez MA, Cano A, Vela E, Tintoré M, Blanco Y, Montalban X, Graus F, Saiz A.

Mult Scler. 2017 Oct 1:1352458517735191. doi: 10.1177/1352458517735191. [Epub ahead of print]

PMID:
28984163
31.

Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies.

Sepúlveda M, Sola-Valls N, Escudero D, Rojc B, Barón M, Hernández-Echebarría L, Gómez B, Dalmau J, Saiz A, Graus F.

Mult Scler. 2018 Nov;24(13):1753-1759. doi: 10.1177/1352458517731914. Epub 2017 Sep 18.

PMID:
28920766
32.

Antibody-associated CNS syndromes without signs of inflammation in the elderly.

Escudero D, Guasp M, Ariño H, Gaig C, Martínez-Hernández E, Dalmau J, Graus F.

Neurology. 2017 Oct 3;89(14):1471-1475. doi: 10.1212/WNL.0000000000004541. Epub 2017 Sep 6.

33.

Understanding anti-IgLON5 disease.

Graus F, Santamaría J.

Neurol Neuroimmunol Neuroinflamm. 2017 Aug 24;4(5):e393. doi: 10.1212/NXI.0000000000000393. eCollection 2017 Sep. No abstract available.

34.

Vanishing spinal cord after varicella-zoster virus myelitis.

Sepúlveda M, Almeida J, Berenguer J, Solá-Valls N, Saura J, Blanco Y, Llufriu S, Graus F, Saiz A.

Neurol Neuroimmunol Neuroinflamm. 2017 Jun 5;4(4):e364. doi: 10.1212/NXI.0000000000000364. eCollection 2017 Jul. No abstract available.

35.

Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma.

Sepúlveda M, Martinez-Hernandez E, Gaba L, Victoria I, Sola-Valls N, Falgàs N, Casanova-Molla J, Graus F.

Muscle Nerve. 2017 Dec;56(6):E162-E167. doi: 10.1002/mus.25672. Epub 2017 May 16.

PMID:
28439919
36.

Widening the spectrum of inflammatory disorders of the central nervous system.

Graus F.

Curr Opin Neurol. 2017 Jun;30(3):292-294. doi: 10.1097/WCO.0000000000000442. No abstract available.

PMID:
28402991
37.

Clinical manifestations of the anti-IgLON5 disease.

Gaig C, Graus F, Compta Y, Högl B, Bataller L, Brüggemann N, Giordana C, Heidbreder A, Kotschet K, Lewerenz J, Macher S, Martí MJ, Montojo T, Pérez-Pérez J, Puertas I, Seitz C, Simabukuro M, Téllez N, Wandinger KP, Iranzo A, Ercilla G, Sabater L, Santamaría J, Dalmau J.

Neurology. 2017 May 2;88(18):1736-1743. doi: 10.1212/WNL.0000000000003887. Epub 2017 Apr 5.

38.

Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System.

Dalmau J, Geis C, Graus F.

Physiol Rev. 2017 Apr;97(2):839-887. doi: 10.1152/physrev.00010.2016. Review.

39.

DPPX antibody-associated encephalitis: Main syndrome and antibody effects.

Hara M, Ariño H, Petit-Pedrol M, Sabater L, Titulaer MJ, Martinez-Hernandez E, Schreurs MW, Rosenfeld MR, Graus F, Dalmau J.

Neurology. 2017 Apr 4;88(14):1340-1348. doi: 10.1212/WNL.0000000000003796. Epub 2017 Mar 3.

40.

Imaging spectrum of central nervous system complications of hematopoietic stem cell and solid organ transplantation.

Server A, Bargalló N, Fløisand Y, Sponheim J, Graus F, Hald JK.

Neuroradiology. 2017 Feb;59(2):105-126. doi: 10.1007/s00234-017-1804-4. Epub 2017 Mar 2. Review.

PMID:
28255902
41.

Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis.

Torres-Vega E, Mancheño N, Cebrián-Silla A, Herranz-Pérez V, Chumillas MJ, Moris G, Joubert B, Honnorat J, Sevilla T, Vílchez JJ, Dalmau J, Graus F, García-Verdugo JM, Bataller L.

Neurology. 2017 Mar 28;88(13):1235-1242. doi: 10.1212/WNL.0000000000003778. Epub 2017 Mar 1.

42.

Paraneoplastic cerebellar degeneration associated with anti-ITPR1 antibodies.

Berzero G, Hacohen Y, Komorowski L, Scharf M, Dehais C, Leclercq D, Fourchotte V, Buecher B, Honnorat J, Graus F, Delattre JY, Psimaras D.

Neurol Neuroimmunol Neuroinflamm. 2017 Feb 3;4(2):e326. doi: 10.1212/NXI.0000000000000326. eCollection 2017 Mar. No abstract available.

43.

Investigations in GABAA receptor antibody-associated encephalitis.

Spatola M, Petit-Pedrol M, Simabukuro MM, Armangue T, Castro FJ, Barcelo Artigues MI, Julià Benique MR, Benson L, Gorman M, Felipe A, Caparó Oblitas RL, Rosenfeld MR, Graus F, Dalmau J.

Neurology. 2017 Mar 14;88(11):1012-1020. doi: 10.1212/WNL.0000000000003713. Epub 2017 Feb 15.

44.

Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies.

Carreño M, Bien CG, Asadi-Pooya AA, Sperling M, Marusic P, Elisak M, Pimentel J, Wehner T, Mohanraj R, Uranga J, Gómez-Ibáñez A, Villanueva V, Gil F, Donaire A, Bargalló N, Rumià J, Roldán P, Setoain X, Pintor L, Boget T, Bailles E, Falip M, Aparicio J, Dalmau J, Graus F.

Epilepsy Res. 2017 Jan;129:101-105. doi: 10.1016/j.eplepsyres.2016.12.010. Epub 2016 Dec 15.

45.

Cerebellar ataxia and autoantibodies restricted to glutamic acid decarboxylase 67 (GAD67).

Guasp M, Solà-Valls N, Martínez-Hernández E, Gil MP, González C, Brieva L, Saiz A, Dalmau J, Graus F, Ariño H.

J Neuroimmunol. 2016 Nov 15;300:15-17. doi: 10.1016/j.jneuroim.2016.09.019. Epub 2016 Oct 5.

46.

Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome.

Sabater L, Planagumà J, Dalmau J, Graus F.

J Neuroinflammation. 2016 Sep 1;13(1):226. doi: 10.1186/s12974-016-0689-1.

47.

Role of (18)F-FDG-PET imaging in the diagnosis of autoimmune encephalitis - Authors' reply.

Graus F, Dalmau J.

Lancet Neurol. 2016 Sep;15(10):1010. doi: 10.1016/S1474-4422(16)30130-2. Epub 2016 Aug 8. No abstract available.

PMID:
27571150
48.

Anti-LGI1-associated cognitive impairment: Presentation and long-term outcome.

Ariño H, Armangué T, Petit-Pedrol M, Sabater L, Martinez-Hernandez E, Hara M, Lancaster E, Saiz A, Dalmau J, Graus F.

Neurology. 2016 Aug 23;87(8):759-65. doi: 10.1212/WNL.0000000000003009. Epub 2016 Jul 27.

49.

Anti-Ma and anti-Ma2-associated paraneoplastic neurological syndromes.

Ortega Suero G, Sola-Valls N, Escudero D, Saiz A, Graus F.

Neurologia. 2018 Jan - Feb;33(1):18-27. doi: 10.1016/j.nrl.2016.05.010. Epub 2016 Jul 25. English, Spanish.

50.

Ephrin-B2 prevents N-methyl-D-aspartate receptor antibody effects on memory and neuroplasticity.

Planagumà J, Haselmann H, Mannara F, Petit-Pedrol M, Grünewald B, Aguilar E, Röpke L, Martín-García E, Titulaer MJ, Jercog P, Graus F, Maldonado R, Geis C, Dalmau J.

Ann Neurol. 2016 Sep;80(3):388-400. doi: 10.1002/ana.24721. Epub 2016 Aug 2.

Supplemental Content

Support Center